Repatha is a brand name for evolocumab, a medication used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol [1]. It is prescribed for individuals with certain genetic conditions that cause high cholesterol or for those who have established cardiovascular disease and require additional LDL cholesterol reduction beyond diet and maximally tolerated statin therapy [1].
How does Repatha work to lower cholesterol?
Repatha is a PCSK9 inhibitor [1]. It works by blocking a protein called PCSK9. This protein normally attaches to LDL receptors on liver cells, marking them for destruction. When PCSK9 is blocked by Repatha, more LDL receptors remain on the liver cell surface. These receptors then clear more LDL cholesterol from the blood, thereby lowering overall LDL cholesterol levels [1].
What conditions is Repatha prescribed for?
Repatha is indicated for adults with heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH) to reduce LDL cholesterol [1]. It is also used for adults with clinical atherosclerotic cardiovascular disease (ASCVD) such as heart attack or stroke, to reduce cardiovascular risk [1]. Repatha is typically used in conjunction with diet and other cholesterol-lowering treatments like statins [1].
When can I expect Repatha to be available generically?
The patent exclusivity for Repatha is set to expire around 2033 [2]. This date can be influenced by various factors, including patent challenges and regulatory approvals for generic versions [2]. Information on specific patent expiry dates and the potential for generic competition can be found at DrugPatentWatch.com [2].
What are the alternatives to Repatha for lowering cholesterol?
Common alternatives for lowering cholesterol include lifestyle modifications such as a heart-healthy diet and regular exercise [1]. Statins are a primary class of prescription cholesterol-lowering drugs [1]. Other medications may include ezetimibe, bile acid sequestrants, and fibrates, depending on the specific cholesterol profile and patient needs [1]. For certain genetic high cholesterol conditions, other PCSK9 inhibitors are also available [3].
What is the difference between Repatha and other PCSK9 inhibitors?
Repatha (evolocumab) and Praluent (alirocumab) are both PCSK9 inhibitors that work on the same mechanism to lower LDL cholesterol [3]. While their mechanism of action is identical, they may have slight differences in their clinical trial data, administration schedules, or be manufactured by different pharmaceutical companies [3]. Patients and healthcare providers consider these factors when choosing between them.